Ardent Health Reports Q4 2025 Profit Decline, Issues Lower 2026 Guidance Amid Headwinds
ARDT is trading near its 52-week low of $8.07 (5.9% above the low).
Summary
Ardent Health reported a sharp decline in Q4 2025 profits and issued 2026 guidance that projects lower Adjusted EBITDA and diluted EPS compared to 2025 actuals, citing various industry headwinds.
Key Events · Earnings and Guidance · ARDT
-
Q4 2025 Profitability Decline
Net income attributable to Ardent Health, Inc. decreased to $45 million in Q4 2025 from $114 million in Q4 2024. Adjusted EBITDA fell 26.6% year-over-year to $134 million.
-
Lower 2026 Financial Guidance
The company issued full-year 2026 Adjusted EBITDA guidance of $485 million to $535 million, which is below the $545 million achieved in full-year 2025. Diluted EPS guidance for 2026 is $0.90 to $1.27, also indicating a potential decline from 2025's $0.96.
-
Operational Headwinds Cited
Management attributed the cautious 2026 outlook to annualization of elevated professional fees, payor denials, Exchange disruption, and restoration of short-term compensation.
-
Modest Share Repurchase
During Q4 2025, the company repurchased 0.35 million shares for $3 million, with $47 million remaining under its authorization. This is a minor positive against the broader financial results.
Analysis · ARDT · Industrial Applications And Services
Ardent Health, Inc. reported a significant year-over-year decline in profitability for Q4 2025, with net income attributable to the company falling to $45 million from $114 million and Adjusted EBITDA decreasing by 26.6% to $134 million. While full-year 2025 revenue and Adjusted EBITDA showed growth, the company's initial full-year 2026 guidance projects a notable decrease in profitability, with Adjusted EBITDA expected to be between $485 million and $535 million, down from $545 million in 2025. Diluted EPS guidance for 2026 also indicates a potential decline. Management cited headwinds including elevated professional fees, payor denials, Exchange disruption, and restoration of short-term compensation. This negative outlook, following recent class action lawsuits, suggests ongoing operational challenges that could impact investor sentiment.
At the time of this filing, ARDT was trading at $8.55 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $8.07 to $15.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.